Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinshen Granules is a Traditional Chinese Medicine (TCM) botanical product developed by Suzhou Yusen New Drug Development Co., Ltd. It is primarily indicated for the treatment of angina pectoris in patients with coronary heart disease, specifically those presenting with the TCM syndrome of Qi deficiency and blood stasis. The formulation is designed to improve cardiac endurance and alleviate symptoms of myocardial ischemia. It has been evaluated in Phase 2 clinical trials in China (e.g., CTR20140053) to assess its efficacy and safety profile in reducing the frequency and severity of angina attacks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinshen Granules.